KCNH1 and glioblastoma: In the GBM collective, patients with a low expression of Kv10.1 had a median survival of 13 months (95 % CI: 9–17), whereas patients with a high expression of Kv10.1 showed a median survival of 8 months (95 % CI: 5–15.6, p = 0.15, Fig. 2).